First Therapy for High-Risk Neuroblastoma Approved by FDAFirst Therapy for High-Risk Neuroblastoma Approved by FDA

Dinutuximab, an antibody targeting glycolipids on the neuroblastoma cell, used in combination with other therapies has been shown to improve survival. FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news